GCM
ALNY icon

Graham Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Graham Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$679K Buy
+2,256
New +$680K 0.01% 610
2026
Q1 		– Sell
-588
Closed -$234K – 1141
2025
Q4 		$234K Sell
588
-2,427
-80% -$1.07M 0.01% 971
2025
Q3 		$1.37M Sell
3,015
-135
-4% -$55K 0.02% 297
2025
Q2 		$1.03M Buy
3,150
+1,240
+65% +$343K 0.02% 573
2025
Q1 		$516K Sell
1,910
-440
-19% -$113K 0.01% 793
2024
Q4 		$553K Sell
2,350
-1,260
-35% -$331K 0.01% 698
2024
Q3 		$993K Buy
3,610
+1,130
+46% +$294K 0.02% 469
2024
Q2 		$603K Sell
2,480
-5,783
-70% -$913K 0.01% 529
2024
Q1 		$1.23M Buy
+8,263
New +$1.38M 0.02% 363
2023
Q4 		– Sell
-1,427
Closed -$253K – 979
2023
Q3 		$253K Sell
1,427
-342
-19% -$65.3K 0.01% 778
2023
Q2 		$336K Buy
+1,769
New +$351K 0.01% 648
2022
Q4 		– Sell
-11,940
Closed -$2.39M – 1031
2022
Q3 		$2.39M Sell
11,940
-2,525
-17% -$482K 0.09% 173
2022
Q2 		$2.11M Buy
+14,465
New +$2.05M 0.09% 194

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's ALNY Position: Q2 2026 in Review

Graham Capital Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 2,256 shares worth $679K. The stake represents 0.01% of the portfolio and ranks #610 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in ALNY as recently as Q4 2025.

Graham Capital Management first reported a position in ALNY in Q2 2022 and has held it in 13 quarters since. The position peaked at $2.39M in Q3 2022. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Graham Capital Management held 2,256 shares of Alnylam Pharmaceuticals worth $679K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Graham Capital Management position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #610 holding.
  • Graham Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
  • Graham Capital Management's Alnylam Pharmaceuticals position peaked at $2.39M in Q3 2022.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.